Essayer OR - Gratuit
Making India A $100-bn Biomanufacturing Hub By 2024
Express Pharma
|February 16-29, 2020
Industry experts outline how Prime Minister Narendra Modi's dream of 'Make in India' for the biomanufacturing sector can be fulfilled in the stipulated time frame
As the year 2020 began, Prime minister Narendra Modi came up with good news for the biotechnology sector. Speaking at the inauguration of the 107th session of the Indian Science Congress at the University of Agricultural Sciences in Bengaluru last month, Modi said, “We aim to develop India as a world-class $100-billion biomanufacturing hubby 2024.”
“The growth story of India depends on its achievements in the science and technology sector. There is a need to revolutionize the landscape of Indian science, technology and innovation. My motto for the young scientists burgeoning in this country has been -innovate, patent, produce and prosper. These four steps will lead our country towards faster development. If we innovate, we will patent and that, in turn, will make our production smoother and when we take these products to the people of our country, they will prosper. Innovation for the people and by the people is the direction of our ‘New India’,” he added.
While the biotechnology sector is one of the key drivers for contributing to India's $5 trillion economy target by 2024, the Indian biotechnology sector is poised to grow exponentially over the next decade. Further, the country is among the top-12 destinations for biotechnology in the world, with approximately three per cent share in the global biotechnology industry.
The biotech sector can be broadly divided into five major segments — biopharma (which accounts for around 55 per cent of the revenue of the total sector), bio-agri (22 per cent of market share), services, bioindustrial and bioinformatics. According to Invest India, the National Investment Promotion and Facilitation Agency, the Indian biotechnology industry was valued at $51-billion in 2018 and is growing at almost 15 per cent year-on-year.
Potential that the biotechnology sector holds
Cette histoire est tirée de l'édition February 16-29, 2020 de Express Pharma.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Express Pharma
Express Pharma
Speed and flexibility play a critical role in how we compete with larger global players
Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma
6 mins
January 2026
Express Pharma
Vizag rising: Shaping India's pharma future
At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth
9 mins
January 2026
Express Pharma
Future of pharma: Trends, challenges & AI
Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies
2 mins
January 2026
Express Pharma
Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments
When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.
1 mins
January 2026
Express Pharma
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare
3 mins
January 2026
Express Pharma
The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.
6 mins
January 2026
Express Pharma
Results win customers. Leadership discipline keeps them
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
3 mins
January 2026
Express Pharma
INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF
India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge
8 mins
January 2026
Express Pharma
PRUV® -The original Sodium Stearyl Fumarate
JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago
5 mins
January 2026
Express Pharma
Odisha's pharma pitch
The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury
5 mins
January 2026
Translate
Change font size
